PDF(Pubmed)
Abstract：
BACKGROUND: Chemotherapy for malignant tumors can cause brain changes and cognitive impairment, leading to chemotherapy-induced cognitive impairment (CICI). Current research on CICI has focused on breast cancer and Hodgkin\'s lymphoma. Whether patients with non-Hodgkin\'s lymphoma (NHL) undergoing chemotherapy have cognitive impairment has not been fully investigated.
OBJECTIVE: To investigate whether NHL patients undergoing chemotherapy had cognitive impairments.
METHODS: The study included 100 NHL patients who were required to complete a comprehensive psychological scale including the Brief Psychiatric Examination Scale (MMSE) at two time points: before chemotherapy and within 2 wk of two chemotherapy courses. A language proficiency test (VFT), Symbol Number Pattern Test (SDMT), Clock Drawing Test (CDT), Abbreviated Daily Cognition Scale (ECog-12), Prospective and Retrospective Memory Questionnaire, and Karnofsky Performance Status were used to assess cognitive changes before and after chemotherapy.
RESULTS: The VFT scores for before treatment (BT) and after treatment (AT) groups were 45.20 ± 15.62, and 42.30 ± 17.53, respectively (t -2.16, P < 0.05). The CDT scores were 8 (3.5-9.25) for BT and 7 (2.5-9) for AT groups (Z -2.1, P < 0.05). Retrospective memory scores were 13.5 (9-17) for BT and 15 (13-18) for AT (Z -3.7, P < 0.01). The prospective memory scores were 12.63 ± 3.61 for BT and 14.43 ± 4.32 for AT groups (t -4.97, P < 0.01). The ECog-12 scores were 1.71 (1.25-2.08) for BT and 1.79 (1.42-2.08) for AT groups (Z -2.84, P < 0.01). The SDMT and MMSE values did not show a significant difference between BT and AT groups.
CONCLUSIONS: Compared to the AT group, the BT group showed impaired language, memory, and subjective cognition, but objective cognition and execution were not significantly affected.
OBJECTIVE: To investigate whether NHL patients undergoing chemotherapy had cognitive impairments.
METHODS: The study included 100 NHL patients who were required to complete a comprehensive psychological scale including the Brief Psychiatric Examination Scale (MMSE) at two time points: before chemotherapy and within 2 wk of two chemotherapy courses. A language proficiency test (VFT), Symbol Number Pattern Test (SDMT), Clock Drawing Test (CDT), Abbreviated Daily Cognition Scale (ECog-12), Prospective and Retrospective Memory Questionnaire, and Karnofsky Performance Status were used to assess cognitive changes before and after chemotherapy.
RESULTS: The VFT scores for before treatment (BT) and after treatment (AT) groups were 45.20 ± 15.62, and 42.30 ± 17.53, respectively (t -2.16, P < 0.05). The CDT scores were 8 (3.5-9.25) for BT and 7 (2.5-9) for AT groups (Z -2.1, P < 0.05). Retrospective memory scores were 13.5 (9-17) for BT and 15 (13-18) for AT (Z -3.7, P < 0.01). The prospective memory scores were 12.63 ± 3.61 for BT and 14.43 ± 4.32 for AT groups (t -4.97, P < 0.01). The ECog-12 scores were 1.71 (1.25-2.08) for BT and 1.79 (1.42-2.08) for AT groups (Z -2.84, P < 0.01). The SDMT and MMSE values did not show a significant difference between BT and AT groups.
CONCLUSIONS: Compared to the AT group, the BT group showed impaired language, memory, and subjective cognition, but objective cognition and execution were not significantly affected.
摘要：
背景：恶性肿瘤的化疗可引起脑部变化和认知障碍，导致化疗引起的认知障碍（CICI）。目前有关CICI的研究主要集中在乳腺癌和霍奇金淋巴瘤上。非霍奇金淋巴瘤(NHL)化疗患者是否存在认知障碍尚未得到充分研究。
目的：探讨接受化疗的NHL患者是否存在认知障碍。
方法：该研究包括100名NHL患者，他们需要在两个时间点完成包括简短精神病检查量表（MMSE）在内的综合心理量表：化疗前和两个化疗疗程的2周内。语言能力测试（VFT）符号编号模式测试(SDMT),时钟绘制测试(CDT),缩写每日认知量表（ECog-12），前瞻性和回顾性记忆问卷，和Karnofsky表现状态用于评估化疗前后的认知变化。
结果：治疗前（BT）和治疗后（AT）组的VFT评分分别为45.20±15.62和42.30±17.53（t-2.16，P<0.05）。BT组CDT评分为8分(3.5～9.25),AT组CDT评分为7分(2.5～9)(Z～2.1,P<0.05)。BT的回顾性记忆评分为13.5（9-17），AT的回顾性记忆评分为15（13-18）（Z-3.7，P<0.01）。BT组和AT组前瞻性记忆评分分别为12.63±3.61和14.43±4.32(t-4.97,P<0.01)。BT组和AT组ECog-12评分分别为1.71(1.25~2.08)和1.79(1.42~2.08)(Z~2.84,P<0.01)。BT和AT组之间的SDMT和MMSE值没有显着差异。
结论：与AT组相比，BT组表现出语言障碍，记忆,和主观认知，但客观认知和执行力没有显著影响。
目的：探讨接受化疗的NHL患者是否存在认知障碍。
方法：该研究包括100名NHL患者，他们需要在两个时间点完成包括简短精神病检查量表（MMSE）在内的综合心理量表：化疗前和两个化疗疗程的2周内。语言能力测试（VFT）符号编号模式测试(SDMT),时钟绘制测试(CDT),缩写每日认知量表（ECog-12），前瞻性和回顾性记忆问卷，和Karnofsky表现状态用于评估化疗前后的认知变化。
结果：治疗前（BT）和治疗后（AT）组的VFT评分分别为45.20±15.62和42.30±17.53（t-2.16，P<0.05）。BT组CDT评分为8分(3.5～9.25),AT组CDT评分为7分(2.5～9)(Z～2.1,P<0.05)。BT的回顾性记忆评分为13.5（9-17），AT的回顾性记忆评分为15（13-18）（Z-3.7，P<0.01）。BT组和AT组前瞻性记忆评分分别为12.63±3.61和14.43±4.32(t-4.97,P<0.01)。BT组和AT组ECog-12评分分别为1.71(1.25~2.08)和1.79(1.42~2.08)(Z~2.84,P<0.01)。BT和AT组之间的SDMT和MMSE值没有显着差异。
结论：与AT组相比，BT组表现出语言障碍，记忆,和主观认知，但客观认知和执行力没有显著影响。
